Clinical Trials · NCT03811561
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,500
- Start date
- May 2019
- Locations
- 229 sites, 19 countries
- Primary endpoint
- Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.